摘要
目的探讨艾地苯醌对癫痫患者脑源性神经营养因子(BDNF)、胰岛素样生长因子1(IGF-1)水平及认知功能的影响。方法选取2010年5月至2014年5月东营鸿港医院住院治疗的74例癫痫患者为研究对象,依据随机数字表法分为观察组和对照组,各37例。对照组患者接受口服丙戊酸钠抗癫痫治疗(20 mg/kg,每日3次),观察组患者在接受口服丙戊酸钠治疗的同时加服艾地苯醌(每次30 mg,每日3次)进行联合治疗,两组患者均连续用药3个月。治疗前后分别采用酶联免疫吸附试验检测两组患者血清BDNF、IGF-1的水平,并通过简易智能精神状态检查量表(MMSE)和威斯康星卡片分类测验(WCST)对两组患者治疗前后的认知功能进评价。结果治疗后,观察组患者血清BDNF与IGF-1水平分别为(9.4±3.5)μg/L、(146±32)μg/L,较治疗前[(6.4±2.1)μg/L、(114±38)μg/L]升高,且高于对照组[(6.4±2.4)μg/L、(115±34)μg/L],差异均有统计学意义(P<0.05或P<0.01)。治疗后观察组MMSE评分高于治疗前[(26±6)分比(24±4)分],WCST评分各项(除试验数与完成分类数外)均低于治疗前(P<0.05),且观察组持续错误数、随机错误数、完成分类数低于对照组[27±12比37±16,28±10比34±12,4.2±0.9比4.8±0.7],差异均有统计学意义(P<0.05)。结论艾地苯醌可以降低癫痫患者血清BDNF、IGF-1水平,从而提高患者治疗后的认知功能。
Objective To investigate the effect of idebenone on brain-derived neurotropthic factor （ BDNF） , insulin-like growth factor-1 （ IGF-1 ） levels and cognitive function in patients with epilepsy. Methods A total of 74 patients with epilepsy admitted to Dongying Honggang Hospitalfrom May 2010 to May 2014 were divided into two groups according to random number table method：observation group and con-trol group,37 cases in each group. Patients in the control group were treated with valproate（20 mg/kg） 3 times a day for 3 months. Patients in the observation group received valproate as well as idebenone 30 mg, 3 times a day for 3 months. BDNF,IGF-1 level were recorded in the two groups before and after treatment. The mini-mental state examination （ MMSE） and Wisconsin card sorting test （ WCST） on cognitive function were evaluated in the two groups before and after treatment. Results After treatment, the levels of serum BDNF and IGF-1 in the observation group were （9. 4 ± 3. 5） μg/L,（146 ± 32） μg/L,respectively, increased than before treatment[（6. 4 ± 2. 1） μg/L,（114 ± 38） μg/L],and were higher than the control group [（6.4 ±2.4） μg/L,（115 ±34） μg/L],the difference was statistically significant （P〈0.05 or P〈0. 01）. After treatment,the MMSE score of the observation group was significantly higher than that before treatment [（26 ±6） scores vs （24 ±4） scores],WCST score（except the test number and the number of complete classification） were lower than before treatment （P〈0. 05）,and the number of consistent errors, the number of random errors,the number of complete classification of the observation group were lower than thatofthecontrolgroup[27±12vs37±16,28±10vs34±12,4.2±0.9vs4.8±0.7],thedifferences were statistically significant（P〈0. 05）. Conclusion Idebenone can lower BDNF and IGF-1 levels in serum of patients with epilepsy,thereby enhance cognitive function of the patients after treatment.
出处
《医学综述》
2015年第19期3634-3636,共3页
Medical Recapitulate
